Core Viewpoint - The controlling shareholder of Baicheng Pharmaceutical, Lou Jinfang, has adjusted the upper limit of the share buyback price from no more than 60 yuan per share to no more than 80 yuan per share, while other arrangements remain unchanged [1] Summary by Relevant Sections - Share Buyback Plan - The original plan was to increase holdings within six months starting from June 12, 2025, with a total investment of no less than 50 million yuan and no more than 100 million yuan, representing a cumulative increase of no more than 2.00% of the total share capital [1] - Current Holdings - As of the date of this announcement, Lou Jinfang has already increased holdings by 612,500 shares, accounting for 0.56% of the company's total share capital, with an investment amount of 30.3079 million yuan [1]
百诚医药：控股股东将增持股份计划的价格上限调整为不超过80元/股